DashboardPortfoliosWatchlistCommunityDiscoverScreener
logo
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Create a narrative
COHANCE logo

Cohance Lifesciences Community

NSEI:COHANCE Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

COHANCE logo
Cohance Lifesciences
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 6 Analysts

New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides

Key Takeaways Strategic acquisitions and entry into high-growth segments enhance revenue and margins by tapping into high-value markets like oligonucleotides and ADCs. Diversification and expansion into specialty segments with differentiated technology and M&A bolster competitive advantage and drive predictable, accelerated growth. Strategic acquisition reliance and volatile demand may strain cash flow, impacting financial stability, margins, and long-term earnings if expected synergies aren't realized.
View narrative
₹1.31k
FV
21.1% undervalued intrinsic discount
56.20%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
9 days ago author updated this narrative
₹
Current Price
₹1.04k60.5% undervalued intrinsic discount
%/yr
Decrease
Increase
PastFuture055b2015201820212024202520272030Revenue ₹55.1bEarnings ₹12.3b
Advanced
Level 5, 320 Pitt Street, Sydney
S&P Global Market Intelligence
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2025, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • About Us
  • Our People
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2025 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • Financial Services Guide